ReviewBMC women's health2026
Glycolytic reprogramming in endometriosis: molecular mechanisms, immune modulation, and non-hormonal therapeutic opportunities.
Review in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Endometriosis is a chronic gynecological disorder characterized by ectopic tissue growth and significant morbidity, yet current hormonal and surgical treatments often fail to prevent recurrence or entail severe side effects. Increasing evidence highlights metabolic reprogramming, specifically aerobic glycolysis (the Warburg effect), as a fundamental driver of endometriotic lesion pathogenesis. This narrative review synthesizes current research on the regulatory mechanisms and therapeutic potential of targeting glycolytic dysregulation in endometriosis. We examine the aberrant upregulation of rate-limiting enzymes, including hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), and pyruvate kinase M2 (PKM2), driven by signaling axes such as ALKBH5-HK2, PAK5-PKM2, and S1PR4/mTOR. The review further elucidates how enhanced glycolytic flux and lactate accumulation promote cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) while orchestrating an immunosuppressive microenvironment via M2 macrophage polarization and histone lactylation. Furthermore, we evaluate emerging non-hormonal therapeutic strategies, including specific glycolysis inhibitors and natural compounds, and discuss the utility of immune-metabolic gene signatures for non-invasive diagnosis. Highlighting these metabolic vulnerabilities offers promising avenues for precision medicine to improve clinical management and patient outcomes in endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.